中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 1
Jan.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(1): 133-140

Application of health-related quality of life assessment in patients with chronic hepatitis B and related advances

DOI: 10.12449/JCH250120

  • Department of Infectious Disease，Tongji Hospital，Tongji Medical College of Huazhong University of Science and Technology，Wuhan 430030，China

Research funding:

National Key Research and Development Program of China (2023YFC2308600)

More Information
  • Corresponding author: HAN Meifang， mfhan@foxmail.com （ORCID： 0000-0002-1948-8128）
  • Received Date: 2024-05-07
  • Accepted Date: 2024-08-09
  • Published Date: 2025-01-25
    Abstract
  • The transformation of traditional biomedical model into the bio-psycho-social medical model means that the purpose of clinical diagnosis and treatment not only focuses on the disease itself， but also emphasizes the quality of life and happiness index of patients. Since chronic hepatitis B （CHB） is infectious and has high rates of recurrence and progression， patients have to bear many pressures in terms of physiology， psychology， economy， and society， which seriously affects their quality of life. Therefore， it is very important to perform health-related quality of life （HRQoL） assessments for patients with CHB. This article reviews the clinical significance and measurement tools of HRQoL assessments in patients with CHB and summarizes the influencing factors for HRQoL in CHB patients and the measures to improve their HRQoL. This article will provide theoretical support for dynamic monitoring of HRQoL in CHB patients and practical guidance for optimizing the clinical diagnosis and treatment regimens for CHB and improving the quality of life of patients.

     

    • FullText(HTML)
  • loading
    • References(51)
  • [1]
    KAPLAN RM, HAYS RD. Health-related quality of life measurement in public health[J]. Annu Rev Public Health, 2022, 43: 355- 373. DOI: 10.1146/annurev-publhealth-052120-012811.
    [2]
    CHURRUCA K, POMARE C, ELLIS LA, et al. Patient-reported outcome measures(PROMs): A review of generic and condition-specific measures and a discussion of trends and issues[J]. Health Expect, 2021, 24( 4): 1015- 1024. DOI: 10.1111/hex.13254.
    [3]
    HSU YC, HUANG DQ, NGUYEN MH. Global burden of hepatitis B virus: Current status, missed opportunities and a call for action[J]. Nat Rev Gastroenterol Hepatol, 2023, 20( 8): 524- 537. DOI: 10.1038/s41575-023-00760-9.
    [4]
    WU D, HUANG D, NING Q. New strategies for clinical cure and institute of hepatitis B: Viral suppression combined with immune modulation and its road map[J]. J Clin Hepatol, 2018, 34( 5): 919- 925. DOI: 10.3969/j.issn.1001-5256.2018.05.002.

    吴迪, 黄达, 宁琴. 慢性乙型肝炎临床治愈新策略: 病毒抑制联合免疫调节及其路线图[J]. 临床肝胆病杂志, 2018, 34( 5): 919- 925. DOI: 10.3969/j.issn.1001-5256.2018.05.002.
    [5]
    van der PLAS SM, HANSEN BE, de BOER JB, et al. The liver disease symptom index 2.0; validation of a disease-specific questionnaire[J]. Qual Life Res, 2004, 13( 8): 1469- 1481. DOI: 10.1023/B: QURE.0000040797.17449.c0.
    [6]
    COONS SJ, RAO S, KEININGER DL, et al. A comparative review of generic quality-of-life instruments[J]. Pharmacoeconomics, 2000, 17( 1): 13- 35. DOI: 10.2165/00019053-200017010-00002.
    [7]
    LI YP, HUANG ZJ, ZHANG H, et al. Feasibility of the MOS 36-item short form health survey in the assessment of the quality of life in hepatitis B patients[J]. China Prev Med, 2007, 8( 4): 352- 355. DOI: 10.3969/j.issn.1009-6639.2007.04.007.

    李跃平, 黄子杰, 张宏, 等. SF-36量表在乙型肝炎患者生存质量测量中的可行性评价[J]. 中国预防医学杂志, 2007, 8( 4): 352- 355. DOI: 10.3969/j.issn.1009-6639.2007.04.007.
    [8]
    DEVLIN NJ, BROOKS R. EQ-5D and the EuroQol Group: Past, present and future[J]. Appl Health Econ Health Policy, 2017, 15( 2): 127- 137. DOI: 10.1007/s40258-017-0310-5.
    [9]
    CAI YF, WU HY, YANG ZH. Comparison analysis of European quality of life-5 dimensions with three-level and five-level based on four types of people in China[J]. Chin J Dis Contr Prev, 2020, 24( 10): 1190- 1194. DOI: 10.16462/j.cnki.zhjbkz.2020.10.016.

    蔡一凡, 伍红艳, 杨智豪. 基于中国四类人群的EQ-5D-3L和EQ-5D-5L量表比较分析[J]. 中华疾病控制杂志, 2020, 24( 10): 1190- 1194. DOI: 10.16462/j.cnki.zhjbkz.2020.10.016.
    [10]
    WANG H, DENG M, SHI LM, et al. The application of the Chinese version of the European quality of life five-dimension scale in China[J]. Chin J Postgrad Med, 2023, 46( 2): 97- 101. DOI: 10.3760/cma.j.cn115455-20220926-00832.

    王惠, 邓明, 时黎明, 等. 欧洲五维健康量表中文版在我国的应用[J]. 中国医师进修杂志, 2023, 46( 2): 97- 101. DOI: 10.3760/cma.j.cn115455-20220926-00832.
    [11]
    HAMMERT WC, CALFEE RP. Understanding promis[J]. J Hand Surg Am, 2020, 45( 7): 650- 654. DOI: 10.1016/j.jhsa.2020.03.016.
    [12]
    DESAI AP, MADATHANAPALLI A, TANG Q, et al. PROMIS Profile-29 is a valid instrument with distinct advantages over legacy instruments for measuring the quality of life in chronic liver disease[J]. Hepatology, 2023, 78( 6): 1788- 1799. DOI: 10.1097/HEP.0000000000000480.
    [13]
    QI MH, HUANG H, DONG JX, et al. Reliability and validity of the Chinese version of the liver disease quality of life questionnaire(LDQOL 1.0)[J]. World Chin J Dig, 2015, 23( 12): 1973- 1979.

    齐明华, 黄海, 董娇璇, 等. 肝病生存质量量表中文版的信度、效度测试[J]. 世界华人消化杂志, 2015, 23( 12): 1973- 1979.
    [14]
    WAN CH, ZHANG XQ, LI XM, et al. Psychometrics of the different scales of the system of quality of life instruments for chronic diseases QLICD[J]. J Kunming Med Univ, 2009, 30( 8): 40- 45.

    万崇华, 张晓磬, 李晓梅, 等. 慢性病患者生命质量测定量表体系QLICD各量表的测量学特性分析[J]. 昆明医学院学报, 2009, 30( 8): 40- 45.
    [15]
    YOUNOSSI ZM, GUYATT G, KIWI M, et al. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease[J]. Gut, 1999, 45( 2): 295- 300. DOI: 10.1136/gut.45.2.295.
    [16]
    CHEN YT. Chinesization of the quality of life scale and its application for non-alcoholic fatty liver disease[D]. Hangzhou: Hangzhou Normal University, 2023.

    陈雨彤. 非酒精性脂肪性肝病特异性生活质量量表的汉化及应用研究[D]. 杭州: 杭州师范大学, 2023.
    [17]
    YOUNOSSI ZM, STEPANOVA M, YOUNOSSI I, et al. Development and validation of a hepatitis B-specific health-related quality-of-life instrument: CLDQ-HBV[J]. J Viral Hepat, 2021, 28( 3): 484- 492. DOI: 10.1111/jvh.13451.
    [18]
    SPIEGEL BMR, BOLUS R, HAN S, et al. Development and validation of a disease-targeted quality of life instrument in chronic hepatitis B: The hepatitis B quality of life instrument, version 1.0[J]. Hepatology, 2007, 46( 1): 113- 121. DOI: 10.1002/hep.21692.
    [19]
    LUO XW, CAI TS. Development of a quality of life scale for patients with chronic hepatitis B[J]. Chin J Clin Psychol, 2010, 18( 3): 317- 319. DOI: 10.16128/j.cnki.1005-3611.2010.03.003.

    罗兴伟, 蔡太生. 慢性乙肝患者生活质量量表的编制[J]. 中国临床心理学杂志, 2010, 18( 3): 317- 319. DOI: 10.16128/j.cnki.1005-3611.2010.03.003.
    [20]
    CORTESI PA, CONTI S, SCALONE L, et al. Health related quality of life in chronic liver diseases[J]. Liver Int, 2020, 40( 11): 2630- 2642. DOI: 10.1111/liv.14647.
    [21]
    ZHOU FQ, WANG WX, WANG FL. Influencing factors of life quality in patients with chronic hepatitis B[J]. Chin Clin Nurs, 2023, 15( 7): 438- 441, 445. DOI: 10.3969/j.issn.1674-3768.2023.07.011.

    周丰勤, 王伟仙, 王凤林. 慢性乙型肝炎患者生存质量影响因素研究[J]. 中国临床护理, 2023, 15( 7): 438- 441, 445. DOI: 10.3969/j.issn.1674-3768.2023.07.011.
    [22]
    ZHANG MD, WAN MJ, WANG W, et al. Effect of interferon therapy on quality of life in patients with chronic hepatitis B[J]. Sci Rep, 2024, 14( 1): 2461. DOI: 10.1038/s41598-024-51292-4.
    [23]
    CHEN P, ZHANG F, SHEN YQ, et al. Health-related quality of life and its influencing factors in patients with hepatitis B: A cross-sectional assessment in Southeastern China[J]. Can J Gastroenterol Hepatol, 2021, 2021: 9937591. DOI: 10.1155/2021/9937591.
    [24]
    LAM ETP, LAM CLK, LAI CL, et al. Health-related quality of life of Southern Chinese with chronic hepatitis B infection[J]. Health Qual Life Outcomes, 2009, 7: 52. DOI: 10.1186/1477-7525-7-52.
    [25]
    ONG SC, MAK B, AUNG MO, et al. Health-related quality of life in chronic hepatitis B patients[J]. Hepatology, 2008, 47( 4): 1108- 1117. DOI: 10.1002/hep.22138.
    [26]
    ZHANG M, LI YG, FAN ZH, et al. Assessing health-related quality of life and health utilities in patients with chronic hepatitis B-related diseases in China: A cross-sectional study[J]. BMJ Open, 2021, 11( 9): e047475. DOI: 10.1136/bmjopen-2020-047475.
    [27]
    WANG H, MENG MF, FAN LM. Research progress of stigma in patients with hepatitis B[J]. Chin Gen Pract Nurs, 2017, 15( 7): 791- 793. DOI: 10.3969/j.issn.1674-4748.2017.07.008.

    王慧, 孟美芬, 范卢明. 乙型肝炎病人病耻感的研究进展[J]. 全科护理, 2017, 15( 7): 791- 793. DOI: 10.3969/j.issn.1674-4748.2017.07.008.
    [28]
    ALTINDAG A, CADIRCI D, SIRMATEL F. Depression and health related quality of life in non-cirrhotic chronic hepatitis B patients and hepatitis B carriers[J]. Neurosciences(Riyadh), 2009, 14( 1): 56- 59.
    [29]
    WANG YD, SUN YL, ZHANG XJ, et al. Mediating effect of mental resilience on coping style and treatment compliance in patients with chronic hepatitis B[J]. J Beihua Univ Nat Sci, 2024, 25( 2): 239- 243. DOI: 10.11713/j.issn.1009-4822.2024.02.017.

    王元迪, 孙亚丽, 张晓杰, 等. 心理弹性在慢性乙型肝炎患者应对方式与治疗依从性之间的中介效应[J]. 北华大学学报(自然科学版), 2024, 25( 2): 239- 243. DOI: 10.11713/j.issn.1009-4822.2024.02.017.
    [30]
    KARACAER Z, CAKIR B, ERDEM H, et al. Quality of life and related factors among chronic hepatitis B-infected patients: A multi-center study, Turkey[J]. Health Qual Life Outcomes, 2016, 14( 1): 153. DOI: 10.1186/s12955-016-0557-9.
    [31]
    WU XN, HONG J, ZHOU JL, et al. Health-related quality of life improves after entecavir treatment in patients with compensated HBV cirrhosis[J]. Hepatol Int, 2021, 15( 6): 1318- 1327. DOI: 10.1007/s12072-021-10240-4.
    [32]
    LU J, PIAO HX, JIN XM, et al. Correlation of quality of life with aspartate aminotransferase-to-platelet ratio index, liver stiffness measurement, and histopathology after antiviral therapy for chronic hepatitis B liver fibrosis[J]. J Clin Hepatol, 2021, 37( 4): 813- 816. DOI: 10.3969/j.issn.1001-5256.2021.04.018.

    卢晶, 朴红心, 金雪梅, 等. 慢性乙型肝炎肝纤维化抗病毒治疗后生活质量与AST/PLT比率、肝硬度值、病理组织学的相关性分析[J]. 临床肝胆病杂志, 2021, 37( 4): 813- 816. DOI: 10.3969/j.issn.1001-5256.2021.04.018.
    [33]
    LI JX, WANG Q, CHEN Y. Correlation between oral antiviral drug compliance and quality of life in patients with chronic hepatitis B and the impacting factors of compliance[J]. China Med Pharm, 2023, 13( 6): 126- 130. DOI: 10.3969/j.issn.2095-0616.2023.06.033.

    李佳鑫, 王清, 陈雁. 慢性乙型肝炎患者口服抗病毒药物依从性与生活质量的相关性及其影响因素[J]. 中国医药科学, 2023, 13( 6): 126- 130. DOI: 10.3969/j.issn.2095-0616.2023.06.033.
    [34]
    ABU-FREHA N, TAILAKH M ABU, FICH A, et al. Adherence to anti-viral treatment for chronic hepatitis B[J]. J Clin Med, 2020, 9( 6): 1922. DOI: 10.3390/jcm9061922.
    [35]
    DENG W, JIANG TT, BI XY, et al. Progress on the treatment of chronic hepatitis B with interferons[J/CD]. Chin J Liver Dis(Electronic Version), 2023, 15( 2): 1- 6. DOI: 10.3969/j.issn.1674-7380.2023.02.001.

    邓雯, 蒋婷婷, 毕潇月, 等. 干扰素治疗慢性乙型肝炎研究进展[J/CD]. 中国肝脏病杂志(电子版), 2023, 15( 2): 1- 6. DOI: 10.3969/j.issn.1674-7380.2023.02.001.
    [36]
    WU D, WANG P, HAN MF, et al. Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: The endeavor study[J]. Hepatol Int, 2019, 13( 5): 573- 586. DOI: 10.1007/s12072-019-09956-1.
    [37]
    NING Q, HAN MF, SUN YT, et al. Switching from entecavir to PegIFN Alfa-2a in patients with HBeAg-positive chronic hepatitis B: A randomised open-label trial(OSST trial)[J]. J Hepatol, 2014, 61( 4): 777- 784. DOI: 10.1016/j.jhep.2014.05.044.
    [38]
    ABDELAZIZ H, SEIFELDIN S, ELHOSSEINY M, et al. Health related quality of life in chronic hepatitis C patients before and after treatment[J]. QJM, 2020, 113( Supplement_1): hcaa052.046. DOI: 10.1093/qjmed/hcaa052.046.
    [39]
    COFFIN C, ELKHASHAB M, DOUCETTE K, et al. WED-191 Assessment of clinical and patient reported outcome measures in individuals with chronic hepatitis B who clear HBsAg, followed by the Canadian hepatitis B network[J]. J Hepatol, 2023, 78: S1115. DOI: 10.1016/S0168-8278(23)03233-6.
    [40]
    ZHOU XL, ZHOU YT. Effect of stress reaction to mental health of chronic asymptomatic HBV carrier[J]. China J Health Psychol, 2006, 14( 3): 309- 311. DOI: 10.13342/j.cnki.cjhp.2006.03.026.

    周秀莲, 周媛婷. 应激反应对乙肝病毒携带者心理健康的影响[J]. 中国健康心理学杂志, 2006, 14( 3): 309- 311. DOI: 10.13342/j.cnki.cjhp.2006.03.026.
    [41]
    GUO Y, ZHANG XN, SU S, et al. β-adrenoreceptor-triggered PKA activation negatively regulates the innate antiviral response[J]. Cell Mol Immunol, 2023, 20( 2): 175- 188. DOI: 10.1038/s41423-022-00967-x.
    [42]
    LI C, LIU J, WU YF. Advances in immunomodulatory effects of catecholamines in critical illness[J]. Chin Crit Care Med, 2019, 31( 10): 1295- 1298. DOI: 10.3760/cma.j.issn.2095-4352.2019.10.023.

    李超, 刘军, 吴允孚. 儿茶酚胺免疫调节效应的研究进展[J]. 中华危重病急救医学, 2019, 31( 10): 1295- 1298. DOI: 10.3760/cma.j.issn.2095-4352.2019.10.023.
    [43]
    WU F, HU CH, LI YZ, et al. Correlation of psychological distress with quality of life and efficacy of immune checkpoint inhibitors in patients with newly diagnosed stage IIIB-IV NSCLC[J]. J Clin Oncol, 2022, 40( 16_suppl): 12001. DOI: 10.1200/jco.2022.40.16_suppl.12001.
    [44]
    JIANG MP. Study on sleep quality and related factors in patients with chronic hepatitis B[J]. World J Sleep Med, 2022, 9( 4): 609- 611. DOI: 10.3969/j.issn.2095-7130.2022.04.007.

    江漫萍. 慢性乙型肝炎患者睡眠质量现状及相关影响因素研究[J]. 世界睡眠医学杂志, 2022, 9( 4): 609- 611. DOI: 10.3969/j.issn.2095-7130.2022.04.007.
    [45]
    LANNA A, VAZ B, D’AMBRA C, et al. An intercellular transfer of telomeres rescues T cells from senescence and promotes long-term immunological memory[J]. Nat Cell Biol, 2022, 24( 10): 1461- 1474. DOI: 10.1038/s41556-022-00991-z.
    [46]
    PRATHER AA, GURFEIN B, MORAN P, et al. Tired telomeres: Poor global sleep quality, perceived stress, and telomere length in immune cell subsets in obese men and women[J]. Brain Behav Immun, 2015, 47: 155- 162. DOI: 10.1016/j.bbi.2014.12.011.
    [47]
    MARJOT T, RAY DW, WILLIAMS FR, et al. Sleep and liver disease: A bidirectional relationship[J]. Lancet Gastroenterol Hepatol, 2021, 6( 10): 850- 863. DOI: 10.1016/S2468-1253(21)00169-2.
    [48]
    HU DQ, WANG P, WANG XJ, et al. Disease severity and antiviral response in patients with chronic hepatitis B with non-obese NAFLD[J]. J Formos Med Assoc, 2024, 123( 7): 773- 780. DOI: 10.1016/j.jfma.2023.12.001.
    [49]
    HICKMAN IJ, JONSSON JR, PRINS JB, et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life[J]. Gut, 2004, 53( 3): 413- 419. DOI: 10.1136/gut.2003.027581.
    [50]
    HAQ H, HASSALI A, SHAFIE AA, et al. Association between hepatitis B-related knowledge and health-related quality of life[J]. Trop J Pharm Res, 2014, 13( 7): 1163. DOI: 10.4314/tjpr.v13i7.22.
    [51]
    LUO XW, CAI TS. Effects of illness perceptions on quality of life in patients with chronic hepatitis B[C]// The 90th Anniversary Commemorative Meeting of Chinese Psychological Society and the 14th Chinese Psychological Society. Xi’an: Chinese Psychological Association, 2011: 487.

    罗兴伟, 蔡太生. 慢性乙型肝炎患者疾病认知对生活质量的影响[C]// 中国心理学会成立90周年纪念大会暨第十四届全国心理学学术会议论文集. 西安: 中国心理学会, 2011: 487.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Tables(1)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (102) PDF downloads(24) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return